Collegium Pharmaceutical Inc. (NASDAQ:COLL)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group in a research report issued on Friday. They presently have a $24.00 price target on the specialty pharmaceutical company’s stock. Jefferies Group’s target price indicates a potential upside of 42.52% from the stock’s current price.

COLL has been the topic of a number of other reports. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 26th. Piper Jaffray Cos. set a $23.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, October 12th. Gabelli assumed coverage on shares of Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.00.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 16.84 on Friday. The company has a 50-day moving average price of $16.82 and a 200 day moving average price of $14.23. The company’s market capitalization is $396.21 million. Collegium Pharmaceutical has a one year low of $8.24 and a one year high of $30.58.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. On average, analysts forecast that Collegium Pharmaceutical will post ($3.84) EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of COLL. Nationwide Fund Advisors boosted its stake in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,665 shares during the period. Alliancebernstein L.P. purchased a new stake in Collegium Pharmaceutical during the second quarter worth about $122,000. BlackRock Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.2% in the third quarter. BlackRock Advisors LLC now owns 6,901 shares of the specialty pharmaceutical company’s stock worth $133,000 after buying an additional 857 shares during the period. Royal Bank of Canada boosted its stake in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the period. Finally, Rhumbline Advisers purchased a new stake in Collegium Pharmaceutical during the second quarter worth about $143,000. 61.50% of the stock is currently owned by hedge funds and other institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.